RLYB

Rallybio Corporation

A clinical-stage biotech focused on severe rare diseases, Rallybio is developing therapies like RLYB116, a once-weekly C5 inhibitor, and RLYB332, an antibody for iron-overload conditions. It was founded in 2018 by three former executives of Alexion Pharmaceuticals, who named the company for their mission to "rally" top scientists, partners, and resources from around the globe to pursue treatments other firms had passed over. In early 2026 it agreed to merge with the T-cell engager company Candid, with its legacy drug programs set to be sold off later through special Contingent Value Rights.

CUSIP: 75120L209HealthcareUS1 holder

Feb 6, 2026 — Reclassified from Rallybio Corporation (1:1)

Ownership Activity Financials Filings

Insiders

Ranked by how much each holding moved in all recorded history

Insider

Rocklage Scott M +5 co-filers10% owner · 7 transactions

10.50M—

as of Jun 2022

Bought 615.4K · Sold 460.0K

Hunt RonaldDirector · 3 transactions

6.44M—

as of Aug 2021

Bought 307.7K

Halvorsen Ole Andreas +6 co-filers10% owner · 2 transactions

4.19M—

as of Jul 2021

Bought 806.0K

Parmar KushDirector · 10 transactions

3.63M—

as of Mar 2023

Bought 615.4K · Sold 560.0K

Rocklage Scott M +3 co-filers10% owner · 1 transaction

3.63M—

as of Mar 2023

Sold 100.0K

Shannon Timothy MDirector · 2 transactions

2.41M—

as of Aug 2021

Bought 76.9K

Hopfner Robert LorneDirector · 2 transactions

2.27M—

as of Aug 2021

Bought 576.9K

Schneeberger Daniel +1 co-filer10% owner · 14 transactions

1.76M—

Bought 302.5K

Mackay MartinChief Executive Officer, Director · 4 transactions

991.7K—

as of Jan 2022

Bought 10.0K

Uden StephenSee Remarks · 4 transactions

718.3K—

as of Jan 2022

Bought 10.0K

Fryer Jeffrey MSee Remarks · 8 transactions

521.6K—

as of Mar 2022

Bought 14.4K

FMR LLCSee Remark 1 · 1 transaction

211.8K—

Lieber Jonathan IChief Financial Officer · 3 transactions

4.1K—

Granted 2.5K · Bought 5.0K · Sold 789

Insider	Stake change	Holds now	Granted / vested	Bought	Sold
Rocklage Scott M +5 co-filers10% owner · 7 transactions	—	10.50Mas of Jun 2022	—	615.4K	460.0K
Hunt RonaldDirector · 3 transactions	—	6.44Mas of Aug 2021	—	307.7K	—
Halvorsen Ole Andreas +6 co-filers10% owner · 2 transactions	—	4.19Mas of Jul 2021	—	806.0K	—
Parmar KushDirector · 10 transactions	—	3.63Mas of Mar 2023	—	615.4K	560.0K
Rocklage Scott M +3 co-filers10% owner · 1 transaction	—	3.63Mas of Mar 2023	—	—	100.0K
Shannon Timothy MDirector · 2 transactions	—	2.41Mas of Aug 2021	—	76.9K	—
Hopfner Robert LorneDirector · 2 transactions	—	2.27Mas of Aug 2021	—	576.9K	—
Schneeberger Daniel +1 co-filer10% owner · 14 transactions	—	1.76M	—	302.5K	—
Mackay MartinChief Executive Officer, Director · 4 transactions	—	991.7Kas of Jan 2022	—	10.0K	—
Uden StephenSee Remarks · 4 transactions	—	718.3Kas of Jan 2022	—	10.0K	—
Fryer Jeffrey MSee Remarks · 8 transactions	—	521.6Kas of Mar 2022	—	14.4K	—
FMR LLCSee Remark 1 · 1 transaction	—	211.8K	—	—	—
Lieber Jonathan IChief Financial Officer · 3 transactions	—	4.1K	2.5K	5.0K	789

Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.